retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide: The "Triple G" Peptide

Peptide overview Synonyms: LY3437943

Stewart with a surprising announcement before diving into a conversation about the trending topic of GLP-1 Medications

its a catalyst for positive change in your life

Personalized Digital Twins: The idea of a digital twin isnt limited to hardware

[DOI] [PMC free article] [PubMed] [Google Scholar] 58.Gastaldelli A, Cusi K, Fernndez Land L, Bray R, Brouwers B, and Rodrguez , Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in People With Type 2 Diabetes (SURPASS-3 MRI): A Substudy of the Randomised, Open-Label, Parallel-Group, Phase 3 SURPASS-3 Trial, Lancet Diabetes and Endocrinology 10, no

The reduced stomach size holds less food so you feel full faster, while still allowing for the digestion of key nutrients